JAK3 is an inclusion criterion in 8 clinical trials for acute lymphoblastic leukemia, of which 7 are open and 1 is closed. Of the trials that contain JAK3 status and acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 2/phase 3 (1 open) [4].

JAK3 is an inclusion criterion in 5 clinical trials for B-cell acute lymphoblastic leukemia, of which 3 are open and 2 are closed. Of the trials that contain JAK3 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [4].

JAK3 is an inclusion criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain JAK3 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [4].

JAK3 is an inclusion criterion in 2 clinical trials for malignant solid tumor, of which 1 is open and 1 is closed. Of the trials that contain JAK3 status and malignant solid tumor as inclusion criteria, 2 are phase 2 (1 open) [4].

JAK3 is an inclusion criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 2 are open and 0 are closed. Of the trials that contain JAK3 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2/phase 3 (1 open) [4].

JAK3 is an inclusion criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain JAK3 status and myelodysplastic syndromes as inclusion criteria, 2 are phase 2 (2 open) [4].

JAK3 is an inclusion criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains JAK3 status and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

JAK3 is an inclusion criterion in 1 clinical trial for chronic lymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains JAK3 status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

JAK3 is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains JAK3 status and chronic myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

JAK3 is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains JAK3 status and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

JAK3 is an inclusion criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains JAK3 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

JAK3 is an inclusion criterion in 1 clinical trial for lymphoplasmacytic lymphoma, of which 0 are open and 1 is closed. Of the trial that contains JAK3 status and lymphoplasmacytic lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

JAK3 is an inclusion criterion in 1 clinical trial for lymphoproliferative disorder, of which 0 are open and 1 is closed. Of the trial that contains JAK3 status and lymphoproliferative disorder as inclusion criteria, 1 is phase 1 (0 open) [4].

JAK3 is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains JAK3 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

JAK3 is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, B/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains JAK3 status and mixed phenotype acute leukemia, B/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

JAK3 is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains JAK3 status and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

JAK3 is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains JAK3 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

JAK3 is an inclusion criterion in 1 clinical trial for primary cutaneous T-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains JAK3 status and primary cutaneous T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

JAK3 is an inclusion criterion in 1 clinical trial for secondary acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains JAK3 status and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

JAK3 is an inclusion criterion in 1 clinical trial for splenic marginal zone lymphoma, of which 0 are open and 1 is closed. Of the trial that contains JAK3 status and splenic marginal zone lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

JAK3 is an inclusion criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains JAK3 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

JAK3 is an inclusion criterion in 1 clinical trial for T-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains JAK3 status and T-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

JAK3 is an inclusion criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains JAK3 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

JAK3 is an inclusion criterion in 1 clinical trial for waldenstrom macroglobulinemia, of which 0 are open and 1 is closed. Of the trial that contains JAK3 status and waldenstrom macroglobulinemia as inclusion criteria, 1 is phase 1 (0 open) [4].